FIELD: medicine.
SUBSTANCE: present invention relates to antibodies and their antigen-binding fragments that bind to a cytokine receptor IL-22R, in particular human IL-22R. The invention also relates to an isolated polynucleotide, an expression vector, a host cell, an acellular expression system, a method for producing a recombinant antibody or its antigen-binding fragment, a pharmaceutical composition, a method for the treatment of atopic dermatitis, psoriatic arthritis or psoriasis, the use as a drug, the use in the treatment or prevention of psoriasis, psoriatic arthritis or atopic dermatitis.
EFFECT: obtaining anti-IL-22R-antibodies.
21 cl, 18 dwg, 30 tbl, 17 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CD131-BINDING PROTEINS AND THEIR APPLICATIONS | 2016 |
|
RU2773927C2 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| PD-L1 SPECIFIC ANTIBODIES | 2017 |
|
RU2756236C2 |
| ANTI-PD-L1 AND IL-2 CYTOKINES | 2017 |
|
RU2769282C2 |
| ANTIBODY BINDING HUMAN IL-4R, ANTIGEN-BINDING FRAGMENT THEREOF, AND MEDICAL APPLICATION THEREOF | 2019 |
|
RU2779649C1 |
| ANTIBODY AGAINST IL-5, ITS ANTIGEN-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2772716C2 |
| MONOCLONAL ANTIBODIES TO INTERLEUKIN-31 FOR VETERINARY USE | 2019 |
|
RU2795411C2 |
| ANTIBODIES TO ENTPD2, TYPES OF COMBINATION THERAPY AND METHODS FOR USING ANTIBODIES AND TYPES OF COMBINATION THERAPY | 2019 |
|
RU2790991C2 |
| STAPHYLOCOCCUS AUREUS CLUMPING FACTOR A (ClfA) ANTIBODY | 2019 |
|
RU2818805C2 |
| ADVANCED PROCOAGULANT ANTIBODIES | 2019 |
|
RU2810748C2 |
